Apoptotic pathways in prostate cancer

Advances in Cell Aging and Gerontology

Volumn 6, Issue C, 2001, Pages 23-54

  Denmeade, Samuel R ^a   Tombal, Bertrand ^a   Isaacs, John T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35448978330     PISSN: 15663124     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1566-3124(01)06002-3     Document Type: Review

References (151)

1. An B., and Dou Q.P. Cleavage of retinoblastoma protein during apoptosis: interleukin-1β-converting enzyme-like protease as candidate. Cancer Res. 56 (1996) 438-442
2. Apakama I., Robinson M.C., Walter N.M., Charlton R.G., Royds J.A., Fuller C.E., Neal D.E., and Hamdy F.C. Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Brit. J. Cancer 74 (1996) 1258-1262
3. Ashekenazi A., and Dixit V. Death Receptors: Signaling and modulation. Science 28 (1998) 11305-11308
4. Berges R.S., Furuya Y., Remington L., English H.F., Jacks T., and Isaacs J.T. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc. Natl. Acad. Sci. (USA) 90 (1993) 8910-8914
5. Berges R.S., Vukanovic J., Epstein J.I., Carmichel M., Cisek L., Johnson D.E., Veltri R.W., Walsh P.H., and Isaacs J.T. Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res. 1 (1995) 473-480
6. Bowen I.D., and Lockshin R.A. Cell Death in Biology and Pathology (1981), Chapman and Hall, London
7. Bowen C., Spiegel S., and Gelmann E.P. Radiation-induced apoptosis mediated by retinoblastoma protein. Cancer Res. 58 (1998) 3275-3281
8. Brüne B., Hartzell P., Nicotera P., and Orrenius S. Spermine prevents endonuclease activation and apoptosis in thymocytes. Exp. Cell Res. 195 (1991) 323
9. Buttyan R., Zakeri Z., Lockshin R., and Wolgemuth D. Cascade induction of c-fos, c-myc and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol. Endocrinol. 2 (1988) 650-657
10. Buttyan R., Olsson C.A., Pintar J., Chang C., Bandyk M., Ng P.-Y., and Sawczuk I.S. Induction of the TRPM-2 gene in cells undergoing programmed death. Mol. Cell Biol. 9 (1989) 3473-3481
11. Byrne R.L., Wilson Horne C.H., Robinson M.C., Autzen P., Apakama I., Bishop R.I., Neal D.E., and Hamdy F.C. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Brit. J. Urol. 79 (1997) 190-195
12. Canman C.E., and Kastan M.B. Role of p53 in apoptosis. In: Kaufmann S.H. (Ed). Apoptosis: Pharmacological implications and therapeutic opportunities. Advances in Pharmacology 41 (1997), Academic Press, Inc 429-461
13. 1 mRNA as the androgen repressed mRNA by cDNA cloning and sequence analysis. J. Biol. Chem. 262 (1987) 11901-11903
14. Chen-Levy S., and Cleary M.L. Membrane topology of the Bcl-2 proto-oncogenic protein demonstrated in vitro. J. Biol. Chem. 265 (1990) 4929-4933
15. Chen W.-D., Otterson G.A., Lipkowitz S., Khleif S.N., Coxon A.B., and Faye F.J. Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding. Oncogene 14 (1997) 1243-1248
16. Chinnaiyan A.M., O'Rourke K., Tewari M., and Dixit V.M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81 (1995) 505-512
17. Christensen S.B., Andersen A., Kromann H., Treiman M., Tombal B., Denmeade S.R., and Isaacs J.T. Thapsigargin analogues for targeting programmed death of androgen-independent prostatic cancer cells. Bioorg. Medicinal Chemistry (1999) in press
18. Christensson A., Laurell C.B., and Lilja H. Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 194 (1990) 755-765
19. Chung L.W.K., and Coffey D.S. Biochemical characterization of prostatic nuclei I. androgen-induced changes in nuclear proteins. Biochimica. Biophysica. Acta 247 (1971) 570-583
20. Coffey D.S., Shimazaki J., and Williams-Ashman H.G. Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch. Biochem. Biophys. 124 (1968) 184-198
21. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 326 (1997) 1-6
22. Colombel M., Symmans F., Gil S., O'Toole K.M., Chopin D., Benson M., Olsson C.A., Korsmeyer S., and Buttyan R. Detection of the Apoptosis-Suppressing Oncoprotein bcl-2 in Hormone-Refractory Human Prostate Cancers. Am. J. Pathol. 143 (1993) 390-400
23. Connor J., Sawczuk I.S., Benson M.C., Tomasahefsky P., O'Toole K.M., Olsson C.A., and Buttyan R. Calcium channel antagonists delay regression of androgen-independent tissues and suppress gene activity associated with cell death. Prostate 13 (1988) 119-130
24. Denmeade S.R., Lou W., Lövgren J., Malm H., Lilja H., and Isaacs J.T. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res. 57 (1997) 4924-4930
25. Denmeade S.R., and Isaacs J.T. Enzymatic-Activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer. The Cancer Journal from Scientific American 4 Suppl. 1 (1998) S15-S21
26. Denmeade S.R., Nagy A., Gao J., Lilja H., Schally A., and Isaacs J.T. Enzymatic-activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. 58 (1998) 2537-2540
27. Denmeade S.R., Lin X., Tombal B., and Isaacs J.T. Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells. Prostate (1999) in press
28. Deveraux Q.L., Roy N., Stennicke R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., and Reed J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhbition of distinct caspases. EMBO J. 17 (1998) 2215-2223
29. D'Herde K., and Leybaert L. Intracellular free calcium related to apoptotic death in quail granulosa sheets kept in serum-free culture. Cell Death Different. 4 (1997) 59-65
30. Dowd D.R., MacDonald P.N., Komm B.S., Haussler M.R., and Miesfeld R. Evidence for early induction of calmodulin gene expression in lymphocytes undergoing glucocorticoid-mediated apoptosis. J. Biol. Chem. 266 (1991) 18423-18426
31. Eastman A. Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Sem. Canc. Biol. 6 (1995) 45-52
32. Eisenberger M.A., Blumenstein B.A., Crawford E.D., Miller G., McLeod D.G., Loehrer P.J., Wilding G., Sears K., Culkin D.J., Thompson Jr. I.M., Bueschen A.J., and Lowe B.A. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New England J. Med. 339 (1998) 1036-1042
33. English H.F., Kyprianou N., and Isaacs J.T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15 (1989) 233-251
34. Evan G., and Littlewood T. A Matter of life and cell death. Science 281 (1998) 1317-1321
35. Evans G.S., and Chandler J.A. Cell proliferation studies in the rat prostate: II. The effects of castration and androgen replacement upon basal and secretory cell proliferation. Prostate 11 (1987) 339-352
36. Fesus L., Thomazy V., and Falus A. Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett. 224 (1989) 104-108
37. French L.E., Hahne M., Viard I., Radlgruber G., Zanone R., Becker K., Muller C., and Tschopp J. Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 133 (1996) 335-343
38. Furuya Y., and Isaacs J.T. Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation. Endocrinology 133 (1993) 260-266
39. Furuya Y., Lundmo P., Short A.S., Gill D.L., and Isaacs J.T. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res. 54 (1994) 6167-6175
40. Furuya Y., and Isaacs J.T. Proliferation-dependent vs. independent programmed cell death of prostatic cancer involves distinct gene regulation. The Prostate 25 (1994) 301-309
41. Furuya Y., Walsh J.C., Lin X., Nelson W.G., and Isaacs J.T. Androgen ablation induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinol. 136 (1995) 1898-1906
42. Furuya Y., Krajewski S., Epstein J.I., Reed J.C., and Isaacs J.T. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clinical Cancer Res. (1996) 2389-2398
43. Gavrieli Y., Sherman Y., and Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119 (1992) 493-501
44. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
45. Greenberg D.A. Calcium channels and calcium channel antagonists. Ann. Neurol. 21 (1987) 317-330
46. Grossfeld G.D., Olumi A.F., Connolly J.A., Chew K., Gibney J., Bhargava V., Waldman F.M., and Carroll P.R. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J. Urol. 159 (1998) 1437-1443
47. Hakem R., Hakem A., Duncan G.S., Henderson J.T., Woo M., Soengas M.S., Elia A., de la Pompa J.L., Kagi D., Khoo W., Potter J., Yoshida R., Kaufman S.A., Lowe S.W., Penninger J.M., and Mak T.W. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 94 (1998) 339-352
48. Hanada M., Krajewski S., Tanaka S., Cazals-Hatem D., Spengler B.A., Ross R.A., Biedler J.L., and Reed J.C. Regulation of Bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res. 53 (1993) 4978-4986
49. Hedlund T.E., Duke R.C., Schleicher M.S., and Miller G.J. Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. Prostate 36 (1998) 92-101
50. Hockenbery D., Nuñez G., Milliman C., Schreiber R.D., and Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348 (1990) 334-336
51. Isaacs J.T., Wake N., Coffey D.S., and Sandberg A.A. Genetic Instability Coupled to Clonal Selection as a Mechanism for Tumor Progression in the Dunning R-3327 Rat Prostatic Adenocarcinoma System. Cancer Res. 42 (1982) 2353-2361
52. Isaacs J.T. Hormonally responsive vs unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and G rat prostatic adenocarcinoma. Cancer Res. 42 (1982) 5010-5014
53. Isaacs J.T. Antagonistic effect of androgen on prostatic cell death. Prostate 5 (1984) 545-557
54. Isaacs J.T., and Hukku B. Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer. Prostate 13 (1988) 165-188
55. Isaacs J.T., and Lundmo P.I. Chemotherapeutic induction of programmed cell death in non-proliferating prostate cancer cells. Proc. Am. Assoc. Cancer Res. 33 (1992) 588
56. Isaacs J.T., Lundmo P.I., Berges R., Martikainen P., Kyprianou N., and English H.F. Androgen regulation of programmed death of normal and malignant prostatic cells. J. Andrology 13 (1992) 457-464
57. Isaacs J.T. Role of programmed cell death in carcinogenesis. Env. Health Pers. 101 (1993) 27-34
58. Isaacs J.T. Role of androgens in prostatic cancer. Vitamins and hormones vol. 49 (1994), Academic Press, Inc 433-502
59. Isaacs W.B., Carter B.S., and Ewing C.M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 51 (1991) 4716-4720
60. anicke R.U., Walker P.A., Lin X.Y., and Porter A.G. Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J. 15 (1996) 6969-6978
61. Jayamaran T., and Marks A.R. T cells deficient in 1,4,5-triphosphate receptor are resistant to apoptosis. Mol. Cell. Biol. 17 (1997) 3005-3012
62. Kastan M.B., Zhan Q., El-Deiry W.S., Carrier F., Tyler J., Walsh W.V., Plunkett B.S., Vogelstein B., and Fornace A.J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71 (1992) 587-595
63. Kaufmann S.H., Desnoyers S., Ottaviano Y., Davidson N.E., and Poirier G.G. Specific proteolytic fragmentation of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53 (1993) 3976-3985
64. Kerr J.F.R., Wyllie A.G., and Currie A.R. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 26 (1972) 239-257
65. Kerr J.F.R., and Searle J. Deletion of cells by apoptosis during castration-induced involution of the rat prostate. Virchows. Arch. [Cell Pathol] 13 (1973) 87-102
66. Khan A.A., Soloski M.J., Sharp A.H., Schilling G., Sabatini D.M., Shi-Hua L., Ross C.A., and Snyder S.H. Lymphocyte apoptosis: mediation by increase type 3 inositol 1,4,5-triphosphate receptor. Science 273 (1996) 503-507
67. Kothakota S., Azuma T., Reinhard C., Klippel A., Tang J., Chu K., McGarry T.J., Kirschner M.W., Koths K., Kwiatkowski D.J., and Williams L.T. Caspase-3-generated fragment of gelsolin: Effector of morphological change in apoptosis. Science 278 (1997) 294-298
68. Krajewski S., Tanaka S., Takayama S., Schibler M.J., Fenton W., and Reed J.C. Investigations of the subcellular distribution of the BCL-2 oncoprotein: residence in the neclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 53 (1993) 4701-4714
69. Kuida K., Haydar T.F., Kuan C.-Y., Gu Y., Taya C., Karasuyama H., Su M.S., Rakic P., and Flavell R.A. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 94 (1998) 325-327
70. Kuerbitz S.J., Plunkett B.S., Walsh W.V., and Kastan M.B. Wild-type p53 is a cell cycle checkpoint determinant following radiation. Proc. Natl. Acad. Sci., USA 89 (1992) 7491-7495
71. Kyprinaou N., and Isaacs J.T. Biological significance of measurable androgen levels in the rat ventral prostate following castration. Prostate 10 (1987) 313-324
72. Kyprianou N., and Isaacs J.T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122 (1988) 552-562
73. 2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 13 (1988) 103-117
74. Kyprianou N., and Isaacs J.T. Identification of a cellular receptor for transforming growth factor-B in rat ventral prostate and its negative regulation by androgens. Endocrinology 123 (1988) 2124-2131
75. Kyprianou N., and Isaacs J.T. Expression of transforming growth factor-B in the rat ventral prostate during castration induced programmed cell death. Mol. Endocrinol. 3 (1989) 1515-1522
76. Kyprianou N., and Isaacs J.T. Thymine-less death in androgen independent prostatic cancer cells. Biochem. Biophys. Res. Commun. 165 (1989) 73-81
77. Kyprianou N., and Rock S. Radiation-induced apoptosis of human prostate cancer cells is independent of mutant p53 overexpression. Anticancer Res. 18 (1998) 897-906
78. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 49 (1999) 8-31
79. Lazebnik Y.A., Kaufmann S.H., Desnoyers S., Poirier G.G., and Earnshaw W.C. Reconstitution of the apoptotic cascade in vitro: pivotal role for prICE, a protease resembling interleukin-1B converting enzyme and demonstration that poly(ADP ribose) polymerase is a substrate for this enzyme during apoptosis. Nature 371 (1994) 346-347
80. Leithauser F., Dhein J., Mechtersheimer G., Koretz K., Bruderlein S., Henne C., Schmidt A., Debatin K.M., Krammer P.H., and Moller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 69 (1993) 415-429
81. Levine B., Huang Q., Isaacs J.T., Reed J.C., Griffin D.E., and Hardwick J.M. Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature 361 (1993) 739-742
82. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., and Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1996) 479-489
83. Lin X.S., Denmeade S.R., Cisek L., and Isaacs J.T. The role of growth arrest in programmed (apoptotic) death of prostate cancer cells by thapsigargin. Prostate 33 (1997) 201-207
84. Lipponen P., and Vesalainen S. Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy. Prostate 32 (1997) 9-15
85. Lowe S., Schmitt E.M., Smith S.W., Osborne B.A., and Jacks T. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362 (1993) 847-849
86. Madsen K.R., Fiskum G., and Clawson G.A. Regulation of nuclear scaffold protease activity by calcium. Exp. Cell Res. 187 (1990) 343-345
87. Marcelli M., Cunnigham G.R., Haidacher S.J., Padayatty S.J., Sturgis L., Kagan C., and Denner L. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res. 58 (1998) 76-83
88. Marcelli M., Cunningham G.R., Walkup M., He Z., Sturgis L., Kagan C., Mannuci R., Nicoletti I., Teng B., and Denner L. Signaling pathway activated apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res. 59 (1999) 382-390
89. Martikainen P., and Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 17 (1990) 175-187
90. Martikainen P., Kyprianou N., Tucker R.W., and Isaacs J.T. Programmed death of non-proliferating androgen independent prostatic cancer cells. Cancer Res. 51 (1991) 4693-4700
91. Matsushima H., Kitamura T., Goto T., Hosaka Y., Homma Y., and Kawabe K. Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J. Urol 158 (1997) 2278-2283
92. McConkey D.J., Hartzell P., Nicotera P., and Orrenius S. Calcium-activated DNA fragmentation kills immature thymocytes. FASEB J. 3 (1989) 1843-1849
93. McDonnell T.J., Deane N., Platt F.H., Nunes G., Jaeger U., McKearn J.P., and Korsmeyer S.J. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57 (1989) 79-88
94. McDonnell T.J., Troncoso P., Brisbay S.M., Logothetis C., Chung L.W.K., Hsieh J.-T., Tu S.-M., and Campbell M.L. Expression of the Protooncogene bcl-2 in the Prostate and Its Association with Emergence of Androgen-independent Prostate Cancer. Cancer Res. 52 (1992) 6940-6944
95. McDonnell T.J., Navone N.M., Troncoso P., Pisters L.L., Conti C., Von Eschenbach A.C., Brisbay S., and Logothetis C.J. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J. Urol 157 (1997) 569-574
96. Miyashita T., and Reed J.C. Bcl-2 Gene Transfer Increase Relative Resistance of S49.1 and WEHI7.2 Lymphoid Cells to Cell Death and DNA Fragmentation Induced by Glucocorticoids and Multiple Chemotherapeutic Drugs. Cancer Res. 52 (1992) 5407-5411
97. Miyashita T., and Reed J.C. Bcl-2 Oncoprotein Blocks Chemotherapy- Induced Apoptosis in a Human Leukemia Cell Line. Blood 81 (1993) 151-157
98. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., Hoffman B., and Reed J.C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9 (1994) 1799-1805
99. ontpetit M.L., Lawless K.R., and Tenniswood M. Androgen repressed messages in the rat ventral prostate. Prostate 8 (1986) 25-36
100. Nakamura M., Sakaki Y., Watanabe N., and Takagi Y. Purification and chaqracterization of the Ca plus MG-dependent endodeoxyribonuclease from calf thymus chromatin. Biochem. J. 89 (1981) 143-152
101. Navone N.M., Troncoso P., Pisters L.L., Goodrow T.L., Palmer J.L., Nichols W.W., von Eschenbach A.C., and Conti C.J. p53 Protein Accumulation and Gene Mutation in the Progression of Human Prostate Carcinoma. J. Natl. Cancer Inst. 85 (1993) 1657-1669
102. Noordzij M.A., Bogdanowicz J., Van Krimpen C., Van der Kwast T.H., and Van Steenbrugge G.J. The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients. J. Urol. 158 (1997) 1880-1885
103. Oltvai Z.N., Milliman C.L., and Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 74 (1993) 609-619
104. Owen-Schaub L.B., Radinsky R., Kruzel E., Berry K., and Yonehara S. Anti-Fas on non-hematopoeitic tumors: levels of Fas/APO1 and bcl-2 are not predictive of a biological response. Cancer Res. 54 (1994) 1580-1586
105. 2+ levels. J. Immunol. 154 (1995) 599-609
106. Pegg A.E., Lockwood D.H., and Williams-Ashman H.G. Concentrations of putrescine and polyamines and their enzymic synthesis during androgen-induced prostatic growth. Biochem. J. 117 (1970) 17-31
107. Prins G.S., Birch L., and Greene G.L. Androgen receptor localization in different cell types in the adult rat prostate. Endocrinology 1229 (1991) 3187-3199
108. Quarmby V.E., Beckman Jr. W.C., Wilson E.M., and French F.S. Androgen regulation of c-myc messenger ribonucleic acid levels in rat ventral prostate. Mol. Endocrinol. 1 (1987) 865-874
109. Reed J.C., Cuddy M., Slabiak T., Croce C.M., and Nowell P.C. Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature 336 (1988) 259-261
110. Reed J.C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124 (1994) 1-6
111. Rokhlin O.W., Bishop G.A., Hostager B.S., Waldschmidt T.J., Sidorenko S.P., Pavloff N., Kiefer M.C., Umansky S.R., Glover R.A., and Cohen M.B. Fas-mediated apoptosis in human prostate carcinoma cell lines. Cancer Res. 57 (1997) 1758-1768
112. Rokhlin O.W., Hostager B.S., Bishop G.A., Sidorenko S.P., Glover R.A., Gudkov A.V., and Cohen M.B. Dominant nature of the resistance to Fas- and tumor necrosis factor-a-mediated apoptosis in human prostatic cancer cell lines. Cancer Res. 57 (1997) 3941-3943
113. Rokhlin O.W., Glover R.A., and Cohen M.B. Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7. Cancer Res. 58 (1998) 5870-5875
114. Sasaki Y., Ahmed H., Takeuchi T., Moriyama N., and Kawabe K. Immunohistochemical study of Fas, Fas ligand and interleukin-1B converting enzyme expression in human prostate cancer. Br. J. Urol. 81 (1998) 852-855
115. Sato T., Irie S., Kitada S., and Reed J.C. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 268 (1995) 411-415
116. Sells S.F., Wood D.P., Joshi-Barve S.S., Muthukumar S., Jacob R.J., Crist S.A., Humphreys S., and Rangnekar V.M. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth and Diff. 5 (1994) 457-466
117. Shabaik A.S., Krajewski S., Burgan A., Krajewski M., and Reed J.C. Bcl-2 Protooncogene Expression in Normal, Hyperplastic, and Neoplastic Prostate Tissue. J._Urol. Path. 3 (1995) 17-27
118. Shackney S.E., McCormack G.W., and Cuchural G.J. Growth rate patterns of solid tumors and their relationship to responsiveness to therapy. Ann. Int. Med. 89 (1978) 107-115
119. Shibasaki F., and McKeon F. Calcineurin functions in Ca- activated cell death in mammalian cells. J. Cell Biol. 131 (1995) 735-743
120. Singer G.G., and Abbas A.K. The Fas antigen is involved in peripheral, but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1 (1994) 365-371
121. Snyder R.D. Polyamine depletion is associated with altered chromatin structure in HeLa cells. Biochem. J. 260 (1989) 697-704
122. Squier M.K.T., Miller A.C.K., Malkinson A.M., and Cohen J.J. Calpain activation in apoptosis. J. Cell Physiol. 159 (1994) 229-237
123. Song Q., Lees-Miller S.P., Kumar S., Zhang N., Chan D.W., Smith G.C.M., Jackson S.P., Alnemri E.S., Litwack G., Khanna K.K., and Lavin M.F. DNA-dependent protein kinase catalytic subunit: a target for an ICE-like protease in apoptosis. EMBO J. 15 (1996) 3238-3246
124. Srikanth S.D., and Kraft A.S. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo. Cancer Res. 58 (1998) 834-839
125. Stiens R., and Helpap B. Regressive changes in the prostate after castration. A study using histology, morphometrics and autoradiography with special reference to apoptosis. Pathol. Res. Pract. 172 (1981) 73-87
126. Su X., Zhou T., Wang Z., Yang P., Jope R.S., and Mountz J.D. Defective expression of hematopoeitic cell protein phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis. Immunity 2 (1995) 353-362
127. Susin S.A., Zamzami N., Castedo M., Daugas E., Wang H.G., Geley S., Fassy F., Reed J.C., and Kroemer G. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95-and ceramide-induced apoptosis. J. Exp. Med. 186 (1997) 25-37
128. Takeuchi T., Sasaki Y., Ueki T., Kaziwara T., Moriyama N., Kawabe K., and Kakizoe T. Modulation of growth and apoptosis response in PC-3 and LNCaP prostate-cancer cell lines by Fas. Int J. Cancer 67 (1996) 709-714
129. 2+-ATPase. Proc. Natl. Acad. Sci., USA 87 (1990) 2466-2470
130. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
131. Thornberry N.A. The caspase family of cysteine proteases. British Medical Bulletin 53 (1996) 478-490
132. Thornberry N.A., and Lazebnik Y. Caspases: Enemies within. Science 281 (1998) 1312-1316
133. i in individual cells undergoing apoptosis. Cell Calcium (1999) in press
134. Tsujimota Y., Cossman J., Jaffe E., and Croce C. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228 (1985) 1440-1443
135. Tubina M., and Malaise E.P. In: Symington T., and Carter R.L. (Eds). Scientific Foundation of Oncology (1976), Yearbook Medical, Chicago, IL 126-138
136. Umansky S.R., Korol B.A., and Nelipovich P.A. In vivo DNA degradation in thymocytes of gamma-irradiated or hydrocortisone-treated rats. Biochim. Biophys. Acta 655 (1981) 9
137. Vaux D., Cory S., and Adams J. Bcl-2 promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335 (1988) 440-442
138. Villa P., Kaufmann S.H., and Earnshaw W.C. Caspases and caspase inhibitors. TIBS 22 (1997) 388-393
139. Walton M.I., Whysong D., O'Connor P.M., Hockenbery D., Korsmeyer S.J., and Kohn K.W. Constitutive Expression of Human Bcl-2 Modulates Nitrogen Mustard and Camptothecin Induced Apoptosis. Cancer Res. 53 (1993) 1853-1861
140. Wang J., Campos B., Jamieson Jr. G.A., Kaetzel M., and Dedman J.R. Functional elimination of calmodulin within the nucleus by targeted expression of an inhibitor peptide. J. Biol. Chem. 270 (1995) 30245-30248
141. Watt K.W.K., Lee P.J., Timkulu T.M., Chan W.P., and Loor R. Human prostate-specific antigen; Structural and functional similarity with serine proteases. Proc. Natl. Acad. Sci., U.S.A. 83 (1986) 3166-3170
142. Wyllie A.H. Glucocorticoid induces in thymocytes a nuclease-like activity associated with the chromatin condensation of apoptosis. Nature 284 (1980) 555-556
143. Wyllie A.H., Kerr J.F.R., and Currie A.R. Cell death: the significance of apoptosis. Int._Rev. Cytol. 68 (1980) 251-306
144. Yagoda A., and Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71 (1993) 1098-1109
145. Yan G., Fukabori Y., Nikolaropoulus S., Wang F., and McKeehan W.L. Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin. Mol. Endocrinol. 6 (1992) 2123-2128
146. Yazawa M., Vorherr T., James P., Carafoli E., and Yagi K. Binding of calcineurin by calmodulin: influence of the calmodulin binding domain of the plasma membrane calcium pump. Biochemistry 31 (1992) 3171-3176
147. Yin X.-M., Oltvai Z.N., and Korsmeyer S.J. BH1 and BH2 domains of Bcl-2 are Required for Inhibition of Apoptosis and Heterodimerization with Bax. Nature 369 (1994) 321-323
148. Zhao X., Gschwend J.E., Powell C.T., Foster R.G., Day K.C., and Day M.L. Retinoblastoma-protein-dependent growth signal conflict and caspase activity are required for protein kinase C-signaled apoptosis of prostate epithelial cells. J. Biol. Chem. 272 (1997) 22751-22757
149. Zhivotovsky B., Wade D., Nicotera P., and Orrenius S. Role of nuclease in apoptosis. Int. Arch. Allergy Immunol. 105 (1994) 333-338
150. Zhivotovsky B., Cervedall B., Jiang S., Nicotera P., and Orrenius S. Involvement of Ca in the formation of high molecular weight DNA fragments in thymocyte apoptosis. Biochem. Biophys. Res. Comm. 202 (1994) 120-127
151. Zhivotovsky B., Gahm A., Ankarcrona M., Nicotera P., and Orrenius S. Multiple proteases are involved in thymocyte apoptosis. Exp. Cell Res. 221 (1995) 404-412